Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Off-label use of biologic therapies in patients with pediatric inflammatory bowel disease (IBD) has seen an increase in utilization. In this paper, we review the current state of off-label therapies in the pediatric IBD population. Real-world use of ustekinumab (UST), vedolizumab (VDZ), upadacitinib (UPA), tofacitinib, and ozanimod in the adult population could prove positive outcomes in the pediatric population. Established off-label therapies inch closer to comparable safety, efficacy, and outcomes in pediatric IBD use. Outcomes and use of newer biologic therapies in patients with pediatric IBD have improved with increased rates of steroid-free clinical remission (SFCR). Novel therapies, including Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor (S1Pr) modulators, require further studies but could also prove effective.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258086 | PMC |
| http://dx.doi.org/10.1002/pdi3.70011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK.
J Neurol Neurosurg Psychiatry
September 2025
Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
Background: Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used as a one-off disease-modifying therapy for aggressive forms of multiple sclerosis (MS). We report real-world effectiveness of AHSCT for MS in the UK.
Methods: This retrospective open-label study included patients with (pw)MS treated with AHSCT between 2002 and 2023 in 14 UK centres.
Adenoviral Retinitis: A Rare Case Presentation of a Common Virus.
Ocul Immunol Inflamm
September 2025
Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Purpose: To report a rare case of bilateral necrotising retinitis caused by a potentially novel human adenovirus D (HAdV-D) in a post-bone marrow transplant patient and to highlight the diagnostic challenges and therapeutic role of intravenous cidofovir, alongside a review of previously reported cases of human adenovirus (HAdV) retinitis.
Methods: Retrospective case report.
Results: A 60-year-old man with a history of acute myeloid leukaemia, in remission post-bone marrow transplant, presented with bilateral hypertensive granulomatous panuveitis and necrotising retinitis.
Development and Validation of a Pathomics-Based Prognostic Model for Patients with Lung Adenocarcinoma Undergoing First-Line EGFR-TKI Therapy.
Ann Surg Oncol
September 2025
Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Background: Accurate prognostic prediction is crucial for personalized treatment of patients with lung adenocarcinoma (LUAD) receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This study aims to develop and validate a pathomics-based prognostic model for EGFR-TKI-treated patients with LUAD.
Patients And Methods: Data from 122 patients with LUAD who underwent first-line EGFR-TKI therapy were retrospectively analyzed.
Descriptive Analysis and Factors Associated With Relapse in Dogs With Presumptive Idiopathic Immune-Mediated Polyarthritis.
J Vet Intern Med
September 2025
Ecole Nationale Veterinaire d'Alfort-CHUV-AC-IMRB, Maisons-Alfort, France.
Background: Immune-mediated polyarthritis (IMPA) is a joint disease common in dogs. Although its prognosis is generally favorable, relapses are frequent, and predictive factors for relapse remain poorly characterized.
Objectives: To evaluate the outcome of medical management of IMPA in dogs and identify predictive factors for relapse.
Case Report: Rhabdomyolysis following initiation of tirzepatide.
Front Pharmacol
August 2025
Department of Internal Medicine, University Medicine, Rostock, Germany.
We present the case of a 66-year-old woman who developed weakness, nausea, and vomiting accompanied by markedly elevated creatine kinase levels after first treatment with an increased dose of tirzepatide. Laboratory findings were consistent with rhabdomyolysis and normalized within 4 days following discontinuation of tirzepatide and initiation of supportive intravenous fluid therapy. The temporal relationship strongly suggests tirzepatide as a likely trigger.
View Article and Find Full Text PDF